Ayahuasca Addiction Treatment: What the Evidence Shows

Ayahuasca has been used in Amazonian healing traditions for generations, and for the past three decades a small number of treatment centers have tried to combine that tradition with Western clinical practice. The result is one of the more unusual bodies of evidence in psychedelic medicine. Interest in ayahuasca addiction treatment has grown steadily among people who have cycled through conventional programs without lasting change, which makes an accurate reading of what the research does and does not support more important than usual.

Where Does Ayahuasca Fit in Addiction Work?

Ayahuasca is a brew made from two plants. The Banisteriopsis caapi vine contains compounds called beta-carbolines, principally harmine, harmaline, and tetrahydroharmine. A second plant, usually Psychotria viridis, contains DMT. Taken by mouth on its own, DMT is broken down in the gut before it reaches the brain. The beta-carbolines temporarily block the enzyme responsible for that breakdown, which is what makes the brew orally active. This detail matters because those same beta-carbolines are what create the drug interaction risks discussed later in this post.

A ceremony typically runs four to six hours, usually at night, usually in a group, and usually guided by a facilitator working within a specific lineage. Vomiting is common and is treated in most traditions as part of the process rather than a side effect. Brew strength varies enormously between regions, preparers, and batches, so there is no reliable equivalent of a measured dose. Two cups from different centers can differ several fold in alkaloid content.

The most developed attempt to bridge tradition and clinical care is the Takiwasi Center in Tarapoto, Peru, founded in 1992 by a French physician. Its program is residential and runs for months, combining Amazonian plant preparations, including ayahuasca, with psychotherapy, group work, and structured community living. It is worth understanding this design early, because it explains a recurring problem in the research. When people improve inside a program like that, isolating what the ayahuasca itself contributed is difficult. A fuller picture of the brew, the setting, and the risks is covered in our complete guide to ayahuasca.

What Does the Research on Ayahuasca Addiction Treatment Actually Show?

A small Canadian study of ayahuasca-assisted therapy

The most frequently cited clinical work comes from a rural First Nations community in British Columbia. Researchers followed 12 participants through a four-day program that combined group counseling with two guided ayahuasca ceremonies, then reassessed them six months later. Participants showed statistically significant improvements in hopefulness, empowerment, mindfulness, and quality of life, along with a significant reduction in problematic cocaine use. Self-reported alcohol and tobacco use also declined. Cannabis and opioid use did not change, which is an important qualifier that often disappears when this study is summarized. A follow-up analysis interviewed 11 of those participants and found that they attributed the changes largely to emotional insight and a renewed sense of connection to community rather than to the pharmacology alone.

What long-term ceremonial users look like on addiction measures

A Spanish and Brazilian research team assessed regular ceremonial ayahuasca users using the Addiction Severity Index, a standard clinical interview. In the first comparison, 56 jungle-based users were matched against 56 rural controls. In the second, 71 urban users were compared with 59 urban controls. Both ayahuasca groups scored significantly lower than controls on alcohol use and psychiatric status. Many of the jungle-based participants reported extensive earlier illicit drug use that had since stopped. The finding is striking, though it describes people who chose and stayed with a demanding ceremonial practice, which is a different question from whether ayahuasca causes the improvement.

What large survey data adds

The Global Ayahuasca Project surveyed 8,629 people across more than 40 countries who had consumed ayahuasca in religious, traditional, or non-traditional settings. Ayahuasca consumption was associated with lower current use of alcohol and other drugs, and the association held for people with and without a prior substance use disorder even after adjusting for religious and social group membership. Survey data of this size is useful for identifying patterns worth testing. It cannot establish that ayahuasca produced the difference, since people who drink ayahuasca regularly differ from the general population in many ways.

Why Might Ayahuasca Affect Addictive Patterns?

The pharmacological explanation starts with DMT, which activates serotonin 2A receptors in the prefrontal cortex, the region most involved in self-reflection, motivation, and emotional regulation. That activation appears to open a brief period in which the brain forms new connections more readily than usual, a state researchers call increased neuroplasticity. In plain terms, entrenched patterns become somewhat easier to interrupt for a while afterward.

The beta-carbolines (β-Carbolines) add a second layer. By inhibiting monoamine oxidase, they alter how dopamine and serotonin are cleared, and preclinical work suggests harmine may have effects on neural growth independent of DMT. This part of the picture is still theoretical in humans.

The psychological account may matter just as much. Participants across these studies consistently describe a vivid, often confronting encounter with the origins of their substance use, followed by a shift in how they see themselves. Addiction research has long recognized that durable change tends to follow a change in self-concept rather than a change in willpower. Ayahuasca appears to compress that shift into a short and intense period, which is also why the weeks afterward carry so much weight. Without structured integration support, insight tends to fade back into old routines.

Where the Evidence Falls Short

No randomized controlled trial has tested ayahuasca for substance use disorder in humans. That single fact should anchor any decision. The published work consists of small observational studies, qualitative interviews, cross-sectional comparisons, and self-report surveys, all of which are vulnerable to expectancy effects and self-selection. People who travel to Peru for a residential program are already highly motivated, and motivation alone predicts better outcomes in every form of addiction treatment.

Blinding is also close to impossible with a substance this distinctive, and the ceremonial packaging that may be therapeutically active is exactly what makes it hard to study. Results from month-long residential programs cannot be separated into the contribution of the brew, the psychotherapy, the removal from a using environment, and the community. Ayahuasca has performed better in controlled research on depression, where a placebo-controlled trial has been conducted, and that work is covered separately in our post on ayahuasca and depression. Addiction has no comparable trial.

What Are the Risks, Especially for People Already in Recovery?

Drug interactions are the most serious and most commonly underestimated risk. The beta-carbolines in ayahuasca inhibit monoamine oxidase, so combining the brew with SSRIs, SNRIs, tramadol, stimulants, MDMA, or other serotonergic drugs can trigger serotonin syndrome, which is potentially fatal. Many people seeking help for addiction are also being treated for depression or anxiety, which puts them squarely in this risk category. Stopping an antidepressant to attend a retreat introduces its own danger and must never be done without medical supervision. The specifics are covered in our post on SSRIs and psychedelic therapy.

For opioid dependence the calculation is starker. Buprenorphine and methadone are among the few interventions in medicine with a demonstrated effect on mortality. Discontinuing them to qualify for a retreat reduces tolerance, and if relapse follows, the overdose risk is substantially higher than before. Ayahuasca is not a detox protocol and does not interrupt acute withdrawal.

Physically, ayahuasca raises heart rate and blood pressure, and repeated vomiting can cause dehydration. A history of psychosis or bipolar disorder is a standard exclusion, as are several cardiac conditions, and our overview of who should pause before pursuing psychedelic therapy covers the full list. Screening quality at retreat centers varies widely, and some accept participants that no clinical program would. Before booking anything abroad, read our guidance on evaluating retreats outside the United States.

Is Ayahuasca Legally Available in the United States?

DMT remains a Schedule I controlled substance under federal law, and ayahuasca is treated accordingly. Two narrow exceptions exist for established religious organizations, the União do Vegetal and branches of Santo Daime, which won the right to use the brew as a sacrament through federal religious freedom litigation. Those exemptions apply to their members and ceremonies, not to the public.

Colorado decriminalized personal possession of several natural medicines including DMT, and its law allows regulators to consider adding DMT to the licensed program from June 2026 onward. As things stand, the state’s regulated healing centers are still authorized for psilocybin only. No state currently offers supervised legal access to ayahuasca, which is why most Americans who pursue it travel to Peru, Costa Rica, Brazil, or the Netherlands.

How Does This Fit Alongside Conventional Addiction Treatment?

Nothing in the current evidence supports replacing established addiction care with a ceremony. The reasonable framing is adjunctive, with existing treatment left intact and the medical team informed. If you are in a twelve-step program, it is worth thinking through in advance how a psychedelic experience sits with an abstinence-based framework and how your sponsor is likely to respond, since discovering that conflict afterward tends to be destabilizing.

Ayahuasca is also not the only option, and it is rarely the first one worth considering. Psilocybin has produced stronger controlled data for alcohol use disorder, ketamine is legally accessible throughout the United States, and ibogaine has the most developed literature on interrupting opioid withdrawal despite a serious cardiac risk profile that requires medical monitoring. Our comparison of which psychedelic fits which addiction and our broader overview of addiction and psychedelic therapy set out the trade-offs in detail.

If you are still drawn to this path, the sequence that protects you is straightforward. Review every medication with your prescribing physician first. Ask any center directly about medical screening, on-site emergency capacity, and facilitator training. Arrange integration support before you travel rather than after you return, because the weeks following the experience are where recovery gains are consolidated or lost.